A Trial Comparing Efficacy, Tolerability, and Safety of GZR101 Injection Once Daily (OD) and GZR33-70 Injection OD

NCT06558708 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: GZR101 Injection
DRUG: GZR33 Injection
DRUG: Insulin aspart

Sponsor

Gan and Lee Pharmaceuticals, USA